|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Phase III Randomized Study of High-Dose Cyclophosphamide, Thiotepa, and Carboplatin and Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation in Conjunction With Cyclosporine and Interferon Gamma Versus Interleukin-2 as Immunomodulation in Women With High-Risk Stage II or III Breast Cancer
Alternate Title Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
Objectives
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy: Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Patient Characteristics: Age:
Sex:
Menopausal status:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
Expected Enrollment A total of 70 patients (30 with stage II disease and 40 with stage III disease) will be accrued over 2 years. Outline This is a randomized study. Patients are stratified according to stage (II vs III), age, lymph node status, and inflammatory histology. Patients are randomized to one of two immunomodulation arms. Autologous harvest of at least 1 million CD34+ cells /kg or 400 million mononuclear cells/kg must be achieved. All patients receive cyclophosphamide IV continuously and thiotepa IV continuously over 96 hours on days -6 through -3 and carboplatin IV over 5 hours daily on days -6 through -3. Patients undergo autologous bone marrow and/or peripheral blood stem cell transfusion on day 0.
Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then annually for 5 years. Published ResultsCohen DJ, Vahdat LT, Zipin D, et al.: Randomized trial of low-dose interleukin-2 vs. cyclosporine A and interferon- after high dose chemotherapy with peripheral blood progenitor support in women with high risk primary breast cancer (HRPBC). [Abstract] Breast Cancer Res Treat 88 (1): A-2079, 2004. Trial Lead Organizations Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |